Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lysophosphatidic acid (LPA) signaling via G protein-coupled LPA receptors mediates various biological effects in cancer cells. This study aimed to investigate the roles of LPA receptors in the regulation of cellular functions during tumor progression in
osteosarcoma
cells. Long-term cisplatin (CDDP)-treated MG63-C and MG63-R7-C cells were generated from
osteosarcoma
MG-63 and highly-migratory MG63-R7 cells, respectively.
LPAR2
and LPAR3 expression levels were significantly higher in MG63-C cells than in MG-63 cells, while LPAR1 expression was reduced. MG63-C cells were highly motile, compared with MG-63 cells. MG63-C cell motility was suppressed by LPA
2
knockdown and enhanced by the LPA
1
/LPA
3
antagonist, dioctanoylglycerol pyrophosphate.
LPAR2
and LPAR3 expression levels were significantly elevated in MG63-R7-C cells in comparison with MG63-R7 cells. MG63-R7-C cells were found to be highly invasive, correlating with metalloproteinase-2 activation. MG63-R7-C cells formed large colonies, whereas colony formation was absent from MG63-R7 cells. Notably, MG63-R7-C cell activities were inhibited by LPA
2
knockdown. These results suggest that LPA signaling via LPA
2
plays an important role in the acquisition of malignant properties during tumor progression in MG-63 cells.
...
PMID:Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells. 2985 40
